Haleon (LON:HLN) Now Covered by Analysts at HSBC

Stock analysts at HSBC started coverage on shares of Haleon (LON:HLN) in a research report issued to clients and investors on Thursday, LSE.Co.UK reports. The brokerage set a “buy” rating on the stock.

Separately, Barclays decreased their price objective on Haleon from GBX 390 ($4.85) to GBX 383 ($4.77) and set an “overweight” rating for the company in a research note on Tuesday, April 9th.

Haleon Stock Up 0.6 %

Shares of LON HLN traded up GBX 2 ($0.02) during mid-day trading on Thursday, hitting GBX 321.90 ($4.01). The company had a trading volume of 17,108,071 shares, compared to its average volume of 18,538,906. Haleon has a 1-year low of GBX 306.80 ($3.82) and a 1-year high of GBX 357.65 ($4.45). The company has a market capitalization of £29.39 billion and a PE ratio of 2,926.36. The company has a debt-to-equity ratio of 57.42, a current ratio of 1.04 and a quick ratio of 0.93. The business’s 50-day simple moving average is GBX 324.31 and its 200 day simple moving average is GBX 326.83.

Insider Transactions at Haleon

In other news, insider Tobias Hestler sold 23,564 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of GBX 329 ($4.10), for a total transaction of £77,525.56 ($96,508.85). Corporate insiders own 22.53% of the company’s stock.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.